secwatch.observer — SEC 8-K summary
======================================

Issuer:     TENAX THERAPEUTICS, INC. (TENX)
CIK:        0000034956
Form:       8-K
Filed at:   2025-06-17T23:59:59+00:00
Accession:  0001654954-25-007104
Event type: other_material
Sentiment:  neutral
Materiality: 0.20
Item codes: 5.03, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tenax Therapeutics shareholders approve officer exculpation, reject meeting-vote mandate
--------------------------------------------------------------------------------

- Shareholders approved officer exculpation amendment (2,458,203 for, 10,244 against); effective upon filing.
- All seven director nominees elected; June Almenoff received 2,460,500 votes in favor.
- Proposal requiring all stockholder action at meetings rejected (1,915,960 for, 563,768 against).
- Non-binding say-on-pay approved (2,435,043 for); advisory vote to occur every two years.
- Cherry Bekaert LLP ratified as auditor for FY2025 (2,976,524 for).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/34956/000165495425007104/0001654954-25-007104-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/34956/000165495425007104/tennx_8k.htm
  HTML page:      https://secwatch.observer/filing/0001654954-25-007104

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer